Novel biomarker-based score (SAD-60) for predicting mortality in patients with COVID-19 pneumonia: a multicenter retrospective cohort of 1013 patientsCOVID-19 폐렴 환자의 사망률 예측을 위한 새로운 바이오마커 기반 점수(SAD-60): 1013명의 환자로 구성된 다기관 후향적 코호트Multicenter Study Published on 2022-06-012022-09-11 Journal: Biomarkers in Medicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] acronym age albumin COVID-19 COVID-19 pneumonia CURB CURB-65 D-dimer death highest hospitalized patient hospitalized patients In-hospital death independent predictors male Mortality multicenter Multivariate analysis NEWS2 novel occurred oxygen oxygen saturation Patient patients patients with COVID-19 peripheral capillary Peripheral capillary oxygen saturation Pneumonia predict Predictive qSOFA representing retrospective retrospective cohort risk SAD-60 score SpO2 with COVID-19 [DOI] 10.2217/bmm-2021-1085 PMC 바로가기 [Article Type] Multicenter Study
Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort StudyResearch article Published on 2022-05-162022-10-05 Journal: Current Therapeutic Research [Category] 신약개발, 임상, 치료법, [키워드] Adverse reaction Clin clinical coronavirus disease COVID-19 CT-P59 death deaths Deterioration discharged efficacy end point Exp Fever Hospitalization indicate mechanical ventilation median time Mild-to-moderate oxygen oxygen saturation p value Patient patients deteriorating patients with COVID-19 performed peripheral capillary phase Placebo Prevent proportion reduced regdanvimab Remdesivir required Result retrospective cohort study Retrospective study risk SARS-CoV-2 single hospital SOC Standard of care sustained treated Two patient [DOI] 10.1016/j.curtheres.2022.100675 [Article Type] Research article
Effects of Face Masks on Physical Performance and Physiological Response during a Submaximal Bicycle Ergometer TestArticle Published on 2022-01-182022-10-29 Journal: International Journal of Environmental Research an [Category] Coronavirus, SARS, [키워드] Affect analyzed Bicycle blood pressure breathing frequency cardiorespiratory change changes in Community COVID-19 COVID-19 pandemic Effect effort Ergometer exhalation valve face Face mask Factor females Infection prevention investigated Likert scale males Mask Masks occupational health and safety oxygen participated Perceived performance peripheral capillary Personal protective equipment physical physical demand physical working capacity physiological physiological response protocol Randomized required response secondary Sex Side effect subject Test wearing face mask were measured [DOI] 10.3390/ijerph19031063 PMC 바로가기 [Article Type] Article
Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19Article Published on 2021-12-092022-10-04 Journal: Nature Communications [Category] 치료기술, 치료법, [키워드] aggregate aggregation Analysis arteriole Autopsy Blood characteristic characterized circulating platelet Concentration COVID-19 COVID-19 patient COVID-19 patients Diagnostic markers Endothelial dysfunction flow cytometry hearts imaging incidence Lab-on-a-chip lack Lungs massive microthrombi microthrombus Microvascular thrombosis Mortality multiorgan failure other organs patients with COVID-19 peripheral capillary Platelet resulting reveal severity shown single-cell statistically thrombotic Vascular widespread [DOI] 10.1038/s41467-021-27378-2 PMC 바로가기 [Article Type] Article
COVID-19 Pneumonia and Dengue Fever Coinfection in an Individual From Southeast AsiaInternal Medicine Published on 2021-10-172022-10-31 Journal: Cureus [Category] COVID-19, [키워드] 24 hours abdomen Acute liver injury acute respiratory syndrome Aede arthralgia Asia caused Chest chills Coagulation Coinfection Contact coronavirus COVID-19 COVID-19 infection COVID-19 pneumonia cycle threshold Dengue Dengue fever dengue virus Diabetes Mellitus Diagnosis Diseases Evidence female Fever FIVE Flaviviridae Ground glass opacity Hepatitis hepatitis B HIV hospital Human immunodeficiency virus hypertension IgG IgM illness Immunoglobulin individual individuals intravenous ischemic heart disease Liver function test lung Lungs male myalgia oxygen saturation pandemic Paracetamol Patient PCR peripheral capillary Pneumonia polymerase chain positive Rash rigors risk factor SARS-CoV-2 serology similarity Sodium chloride tested the patient thrombocytopenia transmitted Treatment vital sign zone [DOI] 10.7759/cureus.18846 PMC 바로가기 [Article Type] Internal Medicine
Melatonin effects on sleep quality and outcomes of COVID‐19 patients: An open‐label, randomized, controlled trialRandomized Controlled Trial Published on 2021-09-082022-10-04 Journal: Journal of medical virology [Category] 임상, [키워드] N‐acetyl‐5‐methoxytryptamine 2019‐nCoV Admission ARMS Blood oxygen saturation C‐reactive protein Characteristics clinical trial Combination control arm control group Controlled clinical trial coronavirus disease COVID‐19 COVID‐19 patient COVID‐19 Day Effect Effectiveness evaluate examined Hospitalized hospitalized COVID‐19 patients IMPROVE intensive care laboratory data Lymphocyte count melatonin Mortality no significant difference open‐label outcome oxygen saturation Patient patients peripheral capillary primary endpoint Randomized randomized, controlled trial receiving recruited SARS‐CoV‐2 secondary endpoint significantly significantly higher Sleep sleep quality standard care standard treatment Symptom Tablet Treatment treatment arm Treatment protocol Trial White blood cell [DOI] 10.1002/jmv.27312 PMC 바로가기 [Article Type] Randomized Controlled Trial
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients중증 코로나19 환자 치료에 이버멕틴 추가의 유효성 및 안전성 평가Clinical Trial Published on 2021-04-042022-07-29 Journal: BMC Infectious Diseases [Category] 임상, 치료제, [키워드] added affecting Alter average Azithromycin azithromycin- blood lymphocyte count C-reactive protein can be used cause changes in Clinical improvement clinical recovery clinical response control group control groups COVID-19 COVID-19 disease COVID-19 pandemic COVID-19 pneumonia COVID19 pneumonia CRP D-dimer level D-dimer levels decrease drug Effect effective Effectiveness enteral use evaluate evaluated Favipiravir ferritin FiO2 follow-up period gene mutation gene mutations genetic test genetic tests groups Hydroxychloroquine increase in investigated Ivermectin ivermectin metabolism ivermectin treatment laboratory parameter Laboratory parameters lymphocyte material metabolism Mortality mortality rate mortality rates Mutation oxygen oxygen saturation PaO2 partial pressure Partial pressure of oxygen Patient patients performing sequence analysis peripheral capillary phase 3 study Pneumonia prognostic protocol protocols randomization Randomized reduction in reference treatment Result Sanger method SARS CoV-2 SARS-CoV2 Sequence analysis serum serum C-reactive protein severe COVID-19 severe COVID-19 patient Severe COVID-19 pneumonia single-blind solution SpO2 study group supplementary material the study group toxic effect toxic effects Treatment two groups were excluded were given while PMC 바로가기 [Article Type] Clinical Trial
Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort studyResearch Article Published on 2020-08-062022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, MERS, [키워드] 95%CI activities Admission age albumin C-reactive protein Characteristics characteristics of patient China clinical Cluster cohort study collected computer tomography coronavirus disease-2019 COVID-19 Critically ill Critically ill patient D-dimer demographic diagnosed discharged Disease progression disease severity Factor faster fibrinogen Follow-up Health high risk hospital Hospital admission hospitalisation hypertension individual Infection Jiangsu Laboratory lymphocyte Lymphocyte count multicentre Multivariable regression Older oxygen saturation pandemic Patient patients patients died peripheral capillary Platelet Pneumonia radiological recorded reduce mortality respiratory respiratory rates Result retrospective retrospective cohort study risk risk factor SARS-CoV-2 severe severe COVID-19 severity Support temperature understanding White blood cells with COVID-19 [DOI] 10.1186/s12879-020-05314-x PMC 바로가기 [Article Type] Research Article
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-07-132022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 24 hour 48 hour Activation acute lung injury acute pneumonia acute respiratory distress syndrome Administered Adult age all-cause mortality Amendment antibodies antibody Antibody test anticipated antiviral therapy approval ARDS assessment assigned baseline Biomarker Blood cardiac disease Care change class Clinical improvement clinical study clinical trial complement Complement inhibitor component Computed tomography concealed Concentration conducted Confirmed Controlled coronary syndrome COVID-19 criteria current Day diagnosis of SARS-CoV-2 dialysis discharge dissemination dose Duration Efficacy element eligibility Endotracheal intubation EU Clinical Trial EudraCT evaluate the effect expected failure female patient Final fraction France Germany greater half-live hospital Hospitalization humanized Hypercoagulable state Immunoglobulin Infection Inflammatory inhibitor initiated intensive care Intubated intubation invasive Invasive mechanical ventilation investigator IVIG Japan Lung injury mechanical ventilation medication monoclonal multicenter Neisseria meningitidis Non-invasive number objective Open-label original outcome oxygen participant Patient patients randomized patients with COVID-19 Period peripheral capillary phase Placebo Pneumonia polymerase chain positive airway pressure presenting progression protocol randomised randomised controlled trial randomization randomization list Randomized randomized controlled study Randomly Ravulizumab receive recruitment registry Remdesivir renal respiratory respiratory distress Respiratory distress syndrome routine clinical care Safety screened Screening secondary Serious Adverse Events serum severe acute respiratory distress syndrome coronavirus 2 Severe acute respiratory syndrome severe COVID-19 severe pneumonia SOFA Spain SpO2 Sponsor stratified Study protocol supportive care survival The United States therapy time Treatment treatment-emergent adverse event Ultomiris United Kingdom ventricular Viral website with COVID-19 X-ray [DOI] 10.1186/s13063-020-04548-z PMC 바로가기 [Article Type] Letter
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trialAGILE-ACCORD: COVID-19 치료를 위한 여러 후보 약제의 최적 용량, 안전성 및 효능을 결정하기 위한 무작위, 다기관, 원활한, 적응 I/II상 플랫폼 연구: 무작위 플랫폼에 대한 연구 프로토콜의 구조화된 요약 재판Letter Published on 2020-06-192022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] 9-point ordinal scale acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive added Adult patients Adverse adverse events agent Anti-viral treatment approval Bayesian Blinding candidate Candidates clinical Clinical improvement cloud Cohort cohorts Combination Common Terminology Criteria Community community setting comparator contributing to coronavirus COVID-19 COVID-19 infection CST cytokine cytokine release death defined determine disease dissemination dose EDC Efficacy Efficacy and safety element eligibility criteria eligible England EudraCT evaluated expected for inclusion futility GRADE group hospitalised hospitalised patient Hospitalization in some include Infection intubation Ireland laboratory-confirmed later phase limit Mask Master protocol mechanical ventilation mechanism mechanism of action multi-arm multicentre Multiple nasal prongs non-invasive ventilation North number objective open Open-label opens optimal dose Ordinal Scale organ Other outcome oxygen oxygen saturation oxygen) participant Patient patient population patients peripheral capillary Peripheral capillary oxygen saturation phase Phase I/II Placebo platform Platform study Platform trial Population Prevent progression of disease promise protocol randomisation randomised Rave recruited recruitment Regulatory required respiratory Safety Sample size SARS-CoV-2 SARS-COV-2 infection seamless setup severe acute respiratory syndrome Coronavirus severe disease shown SOC Specific Stage Standard Standard of care status Study protocol the WHO toxicities Toxicity Treatment treatment of COVID-19 Trial Trial registration Ventilation Viral Viral load viral replication website WHO working [DOI] 10.1186/s13063-020-04473-1 PMC 바로가기 [Article Type] Letter